Roxatidine Attenuates Degradation of Extracellular Matrix

Area of Science:

• Biochemistry
• Cell Biology
• Pharmacology

Background:

• Osteoarthritis (OA) is characterized by extracellular matrix degradation, particularly type II collagen and aggrecan, driven by proinflammatory cytokines.
• Roxatidine is a known H2-receptor antagonist approved for treating gastric and duodenal ulcers.
• The potential therapeutic effects of roxatidine on OA are currently unexplored.

Purpose of the Study:

• To investigate the pharmacological effects of roxatidine on Osteoarthritis (OA) pathogenesis.
• To determine if roxatidine can mitigate cytokine-induced extracellular matrix degradation in chondrocytes.
• To elucidate the molecular mechanisms underlying roxatidine's action in OA models.

Main Methods:

• Utilized human chondrosarcoma SW1353 cells stimulated with Tumor Necrosis Factor-alpha (TNF-α).
• Assessed the expression of matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS).
• Analyzed the activation and nuclear translocation of the Nuclear Factor-kappa B (NF-κB) signaling pathway.

Main Results:

• Roxatidine suppressed TNF-α-induced degradation of type II collagen by inhibiting MMP-3 and MMP-13 expression.
• Roxatidine ameliorated TNF-α-induced reduction of aggrecan by inhibiting ADAMTS-4 and ADAMTS-5 expression.
• Roxatidine attenuated TNF-α-induced activation of the NF-κB pathway, including IKK, IκBα phosphorylation, and NF-κB p65 nuclear translocation.

Conclusions:

• Roxatidine demonstrates chondroprotective effects by inhibiting key enzymes involved in extracellular matrix degradation.
• Roxatidine effectively blocks the NF-κB signaling pathway, a critical mediator in OA.
• These findings suggest roxatidine holds potential as a novel therapeutic agent for Osteoarthritis.